ப்ரீம பயோமெட் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from ப்ரீம பயோமெட். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In ப்ரீம பயோமெட் Today - Breaking & Trending Today
Investors buoyed by positive data for Immutepâs immunotherapy Save Share Small cap immunotherapy biotech Immutep is a step closer to commercialising its leading drug candidate, âeftiâ, after releasing promising data showing the effectiveness of the drug in treating various types of lung, head and neck, and solid tumour cancers. Immutep CEO Marc Voigt says LAG-3 immunotherapies are now getting noticed by the biotech community. The positive clinical trial data will be a boon for the business, which is already trading up 58.3 per cent for the year-to-date at 66¢, thanks to the growing interest from the global biotech community in the LAG-3 checkpoint, which Immutep is targeting. This interest has been driven by the progress that Bristol Myers Squibb has made with its own LAG-3 immunotherapy. ....
Small cap biotech Immutep soars 10.5pc on Merck deal Save Share Small cap biotech Immutep inked its second deal with $248 billion global giant Merck on Tuesday, sending its shares soaring almost 10.5 per cent. The company, which is developing immunotherapy treatments for cancer, infectious diseases and autoimmune disease, signed a deal to conduct a phase 2B clinical trial for head and neck squamous cell carcinoma (a type of cancer) patients, examining the safety and efficacy of Immutepâs lead therapy candidate, eftilagimod alpha (known as efti or IMP321), when given in combination with Merckâs blockbuster immunotherapy drug, Keytruda. The study will compare the combination of drugs, with the effectiveness of Keytruda on its own. ....
Efti clinical trial status updates Excellent financial position following recent US$7.7 million warrant exercise, with cash runway extended beyond end of calendar year 2022 Sydney, AUSTRALIA, Dec. 15, 2020 (GLOBE NEWSWIRE) Immutep (Formerly known as Prima Biomed) Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, provides an update on efti clinical programs. Eftilagimod alpha (“efti”) Update AIPAC - Phase IIb clinical trial The Company presented in a spotlight presentation at the San Antonio Breast Cancer Symposium 2020, first Overall Survival (OS) data and is on track to report final overall survival data and overall response rate by mid calendar year 2021. Currently there are more than 66% of events compared to approx. 60% which were the basis of the OS data presented at the San Antonio Breast Cancer Conference. ....